PPT-Randomized Comparison of Ibrutinib Versus Ofatumumab in Rel

Presented By John Byrd at 2014 ASCO Annual Meeting Background Presented By John Byrd at 2014 ASCO Annual Meeting RESONATE Phase 3 Study Design Presented By John Byrd at 2014 ASCO Annual Meeting. COMPLETE VASULAR ACC THELELEKINKRESISTANTSUPERARROW-FLESHEATHINTRO Tele ex is a leading global provider of specialty medical devices used for diagnostic and therapeutic procedures in critical care, u Gertler. , P. J.; Martinez, S., . Premand. , P., Rawlings, L. B. and . Christel. M. J. . Vermeersch. , 2010, Impact Evaluation in Practice: Ancillary Material, The World Bank, Washington DC (www.worldbank.org/ieinpractice). The content of this presentation reflects the views of the authors and not necessarily those of the World Bank. . Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . Versus Letrozole Plus Placebo in Postmenopausal Women with ER+/HER2- Early Stage Breast Cancer Cristina Saura, 1,2 Evandro de Azambuja, 3 Peter Dubsky, 5,6 Mafalda Oliveira, 1,2 Kamal S. Saini, 4 Richard R. Furman, MD. CLL Research Center. BCR-associated Kinases:. Proven Effective Therapeutic Targets. Nat Rev Immunol 2:945. Syk (spleen tyrosine kinase. ):. fostamatinib. PRT062070. GS-9973. Btk (Bruton’s . RESONATE . (PCYC-1112) Trial of Ibrutinib Compared With Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Paul M. Barr, John C. Byrd,. . Jennifer . R. Brown. Overview. Overview (cont). Ibrutinib. -R. elated Cardiovascular A. E. s. Atrial Fibrillation. Ibrutinib-Related AF Data From 2016 ASH Conference. Wiczer et al Data. Risk Stratification. . Mechanisms of Ibrutinib-Related Cardiotoxicity. . A Brief Update of an Ongoing Trial. Jeff Jones, MD, MPH. 16 May 2015. 2. P. LYN. BCR. CD79a. CD79b. SYK. BTK. PLC. γ. IBRUTINIB. GROWTH. SURVIVAL. B-cell Receptor is the “Accelerator” of B-cells. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP Clinical Pharmacy Specialist, Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Panelist Matthew Snyder, PharmD, BCOP Evolving Treatment Strategies. for CLL/SLL and MCL. Beth Faiman PhD, MSN, APRN-BC, AOCN. Nurse Practitioner. Department of Hematology and Medical Oncology. Cleveland Clinic Taussig Cancer Institute. Cleveland, Ohio. Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . Davids. , MD, . MMSc. . Disclosures for . Ms. . Montegaard. Advisory Committee . Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company . Consulting Agreements . Conflict of Interests. I declare NO relevant conflict of interests in:. Honoraria: . no. Consulting: . no. Research funding: . no. Advisory boards: . no. Patents e Royalties: . no. Discussing Off-label.